XML 36 R24.htm IDEA: XBRL DOCUMENT v3.25.1
SUPPLEMENTAL BALANCE SHEET DETAILS (Tables)
3 Months Ended
Mar. 30, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Accounts Receivable Accounts Receivable
In millionsMarch 30,
2025
December 29,
2024
Trade accounts receivable, gross$706 $744 
Allowance for credit losses(7)(9)
Total accounts receivable, net$699 $735 
Schedule of Inventory
Inventory
In millionsMarch 30,
2025
December 29,
2024
Raw materials$216 $225 
Work in process404 404 
Finished goods26 31 
Inventory, gross646 660 
Inventory reserve(109)(113)
Total inventory, net$537 $547 
Schedule of Accrued Liabilities
Accrued Liabilities
In millionsMarch 30,
2025
December 29,
2024
Contract liabilities, current portion$256 $260 
Accrued compensation expenses (1)
198 252 
Accrued taxes payable80 101 
Operating lease liabilities, current portion78 79 
Other, including warranties (2)
122 135 
Total accrued liabilities$734 $827 
_____________
(1)Includes employee separation costs related to restructuring activities.
(2)See table below for changes in the reserve for product warranties.
Schedule of Changes in Reserve for Product Warranties
Changes in the reserve for product warranties were as follows:
In millionsQ1 2025Q1 2024
Balance at beginning of period$18 $21 
Additions charged to cost of product revenue8 12 
Repairs and replacements(9)(13)
Balance at end of period$17 $20 
Schedule Of Restructuring and Related Costs
A summary of the pre-tax restructuring charges is as follows:

In millionsQ1 2025Q1 2024
Cumulative charges recorded since inception
Employee separation costs$31 $$91 
Asset impairment charges (1)
 32 146 
Other costs — 8 
Total restructuring charges (2)
$31 $36 $245 
_____________
(1)For Q1 2024, primarily relates to impairment of right-of-use assets and leasehold improvements for our Foster City campus.
(2)For Q1 2025, $18 million was recorded in SG&A expense, $11 million in R&D expense, with remainder in cost of revenue.
For Q1 2024, $35 million was recorded in SG&A expense and $1 million in R&D expense and primarily related to Core Illumina segment.
A summary of restructuring liability activity during Q1 2025 is as follows:

In millions
Employee Separation Costs (1)
Other CostsTotal
Amount recorded in accrued liabilities as of December 29, 2024
$$$
Additional expense recorded
31 — 31 
Cash payments
(4)(2)(6)
Amount recorded in accrued liabilities as of March 30, 2025
$29 $— $29 
Estimated costs to still be incurred
$15 $— $15 
_____________
(1)It is expected that substantially all of the employee separation related charges will be incurred and paid by the end of Q3 2025.